<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237183</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-01891</org_study_id>
    <secondary_id>NCI-2014-01891</secondary_id>
    <secondary_id>HHSN2612201200035I</secondary_id>
    <secondary_id>NCI2013-02-01</secondary_id>
    <secondary_id>NWU2013-02-01</secondary_id>
    <secondary_id>N01CN00035</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT02237183</nct_id>
  </id_info>
  <brief_title>Iloprost in Preventing Lung Cancer in Former Smokers</brief_title>
  <official_title>A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I trial studies the side effects and best dose of iloprost compared
      with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of
      drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung
      cancer from forming in patients who used to smoke and who have been found to have abnormal
      cells in their mucus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the toxicity of inhalational iloprost or placebo administered to cohorts of
      patients daily for 2 months, given four time a day (QID) in Cohort A followed by twice daily
      (BID) in Cohort B.

      SECONDARY OBJECTIVES:

      I. To evaluate the compliance with BID or QID dosing regimens. II. To evaluate the effect on
      endobronchial histology. III. To evaluate the effect on serum proteins, including
      adiponectin, C1Q and collagen domain containing (ADIPOQ), C9, adenosine triphosphate (ATP)
      synthase, hydrogen (H+) transporting, mitochondrial F1 complex, beta polypeptide (ATP5B),
      carbohydrate sulfotransferase 15 (CHST15), sex hormone-binding globulin (SHBG),
      heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1), quantitated by a highly
      multiplexed aptamer based analysis measuring approximately 1500 proteins.

      IV. To evaluate the effect on endobronchial brushing and biopsy gene expression of
      peroxisome proliferator-activated receptor gamma (PPARgamma), glutathione S-transferase mu
      (GSTmu), carboxylesterase 1 (Ces1), Fos-related antigen 1 (FosL1), cytochrome p4502e1,
      stearoyl coA desaturase 1, tumor necrosis factor (TNF) superfamily member 9, transforming
      growth factor beta (TGFbeta), Jun and a 46 gene panel associated with dysplasia persistence,
      using Affymetrix arrays.

      V. To evaluate the improvement in chronic obstructive pulmonary disease (COPD) as measured
      by arterial blood gas (ABG) (improved ventilation perfusion matching), pulmonary function
      testing, 6 minute walk distance, quality of life (St. George's respiratory questionnaire,
      COPD assessment test [CAT]).

      OUTLINE: Patients are enrolled to Cohort A to completion prior to initiation of Cohort B.

      COHORT A: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive iloprost via inhalation using a nebulizer QID for 60 days.

      ARM II: Patients receive placebo via inhalation using a nebulizer QID for 60 days.

      COHORT B: Patients are randomized to 1 of 2 arms.

      ARM III: Patients receive iloprost via inhalation using a nebulizer BID for 60 days.

      ARM IV: Patients receive placebo via inhalation using a nebulizer BID for 60 days.

      After completion of study treatment, patients are followed up at 30, 60, and 90 days and
      then annually for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Descriptive statistics (mean, standard deviation [SD], median, max, min and range) will be provided for toxicity. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment compliance, measured as the fraction of prescribed inhalations actually administered</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Descriptive statistics (mean, SD, median, max, min and range) will be provided for compliance. Approximate 95% confidence intervals will be used to assess the difference between treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endobronchial brushing gene expression</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will provide descriptive statistics for the effect on endobronchial brushing gene expression, focusing on prostacyclin-targeted pathways.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression of dysplastic lesions</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will provide descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in COPD</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will provide descriptive statistics for the improvement in COPD as measured by ABG (improved ventilation perfusion matching), pulmonary function testing, 6 minute walk distance, and quality of life (St. George's respiratory questionnaire, CAT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of airway histology</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will provide descriptive statistics for the effect on endobronchial histology, with the primary parameter being worst histology at matched sites; additional outcomes will be average histology, dysplasia index and response, as described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum protein profiling</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Will provide descriptive statistics for the effect on serum proteins as quantitated by aptamer based analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Lung Carcinoma</condition>
  <condition>Mild Dysplasia</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Arm I (iloprost QID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive iloprost via inhalation using a nebulizer QID for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo QID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo via inhalation using a nebulizer QID for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (iloprost BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive iloprost via inhalation using a nebulizer BID for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (placebo BID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo via inhalation using a nebulizer BID for 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost</intervention_name>
    <description>Given via inhalation</description>
    <arm_group_label>Arm I (iloprost QID)</arm_group_label>
    <arm_group_label>Arm III (iloprost BID)</arm_group_label>
    <other_name>Ciloprost</other_name>
    <other_name>Iloprost Clathrate</other_name>
    <other_name>Ventavis</other_name>
    <other_name>ZK 36374</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (iloprost QID)</arm_group_label>
    <arm_group_label>Arm II (placebo QID)</arm_group_label>
    <arm_group_label>Arm III (iloprost BID)</arm_group_label>
    <arm_group_label>Arm IV (placebo BID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given via inhalation</description>
    <arm_group_label>Arm II (placebo QID)</arm_group_label>
    <arm_group_label>Arm IV (placebo BID)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (iloprost QID)</arm_group_label>
    <arm_group_label>Arm II (placebo QID)</arm_group_label>
    <arm_group_label>Arm III (iloprost BID)</arm_group_label>
    <arm_group_label>Arm IV (placebo BID)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (iloprost QID)</arm_group_label>
    <arm_group_label>Arm II (placebo QID)</arm_group_label>
    <arm_group_label>Arm III (iloprost BID)</arm_group_label>
    <arm_group_label>Arm IV (placebo BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have either sputum cytologic atypia of mild dysplasia or greater or
             a history of bronchial biopsy with mild or greater dysplasia within the past 12
             months

          -  Participants must have a smoking history of 20 pack-years or greater

          -  Participants must have the ability to safely undergo bronchoscopy in the judgment of
             the investigators

          -  Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
             =&lt; 1

          -  Leukocytes &gt;= 3,000/microliter

          -  Platelets &gt;= 100,000/microliter

          -  Total bilirubin =&lt; 2.0 mg/dl

          -  Aspartate aminotransferase (AST) (serum glutatmic oxaloacetic transaminase [SGOT])/
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5
             Ã— institutional upper limit of normal (ULN)

          -  Creatinine =&lt; 2.0 mg/dl

          -  Women of child-bearing potential and men having intercourse with a woman of
             childbearing potential must agree to use adequate contraception (hormonal or barrier
             method of birth control; abstinence) prior to study entry and for the duration of
             study participation; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her study physician immediately; Note:
             women are considered to be of child-bearing potential if they are not surgically
             sterile or are under the age of 65 and have menstruated within the last two years

          -  Participants must be able to understand and willing to sign a written informed
             consent document

        Exclusion Criteria:

          -  Participants must not have used any tobacco product in the past year

          -  Participants must not be currently receiving or have previously received
             thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are
             documented again after thiazolidinedione treatment and within 12 months of entry

          -  Participants must not or have been treated with iloprost at any time; Note:
             participants on the placebo arm of previous iloprost trials are eligible, but
             participants on the placebo arm of cohort A of this study may not be enrolled in
             cohort B

          -  Participants must not have used any other investigation agent within the last six
             months

          -  Participants must not have a history of allergic reactions attributed to compounds of
             similar chemical or biologic composition of iloprost

          -  Participants must not have uncontrolled intercurrent illness including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that in the opinion of investigators would jeopardize patient safety of
             data integrity; Note: individuals who are human immunodeficiency virus (HIV) positive
             will not necessarily be excluded, will be considered on a case-by-case basis, but
             will be required to meet criteria related to patient safety and data integrity, as
             assessed by investigators

          -  Participants must not have a current or prior invasive malignancy within the past 6
             months; participants may enroll prior to biopsy result report, unless there are
             findings at bronchoscopy suggesting an invasive malignancy; history of the following
             curatively treated cancers during any time prior to screening is allowed:
             non-melanoma skin cancer, cervical carcinoma in situ, and bladder carcinoma in situ

          -  Participants must not have received either chemotherapy or radiotherapy within the
             previous 6 months; Note: participants receiving long-term adjuvant hormonal therapy
             (such as tamoxifen or aromatase inhibitors for breast cancer) are allowed

          -  Women must not be pregnant or breastfeeding; breastfeeding should be discontinued if
             the mother is treated with iloprost

          -  As iloprost inhibits platelet function, patients must not be taking anticoagulants,
             with the exception of aspirin or other non-steroidal antiinflammatory medications

          -  Due to risk for hypotension in patients on vasodilators or antihypertensive
             medications, participants must not have blood pressure &lt; 95 mm Hg systolic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>York Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver Veterans Administration Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>York E. Miller</last_name>
      <phone>303-393-2869</phone>
      <email>york.miller@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>York E. Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>September 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
